SCHEMBL3673447

SCHEMBL3673447

CCCOc1cccc(C(C)C(=O)O)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.63
KMT2A Q03164 1/20 0.59
AKR1C3 P42330 1/20 0.55
AKR1C2 P52895 1/20 0.55
PTGS2 P35354 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
LMNA P02545 2/20 0.51
ROCK1 Q13464 2/20 0.51
ROCK2 O75116 1/20 0.51
DYRK3 O43781 1/20 0.51
PRKACA P17612 1/20 0.51
RPS6KB1 P23443 1/20 0.51
CDK2 P24941 1/20 0.51
AKT2 P31751 1/20 0.51
GSK3A P49840 1/20 0.51
GSK3B P49841 1/20 0.51
IRAK1 P51617 1/20 0.51
PRKX P51817 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3674440 0.88 AKR1C3 (0.70) PTGS1KMT2AAKR1C3AKR1C2PTGS2
SCHEMBL3668050 0.87 PTGS1 (0.61) PTGS1KMT2AAKR1C3AKR1C2PTGS2
SCHEMBL4128458 0.87 PTGS1 (0.61) PTGS1KMT2AAKR1C3AKR1C2PTGS2
SCHEMBL8784715 0.87 PTGS1 (0.61) PTGS1KMT2AAKR1C3AKR1C2PTGS2
SCHEMBL27678738 0.87 PTGS1 (0.61) PTGS1KMT2AAKR1C3AKR1C2PTGS2
SCHEMBL6513465 0.85 PTGS1 (0.60) PTGS1KMT2AAKR1C3AKR1C2PTGS2
SCHEMBL29071163 0.85 KMT2A (0.59) KMT2ASMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL10455351 0.84 KMT2A (0.57) PTGS1KMT2AAKR1C3AKR1C2SMN1; SMN2
SCHEMBL6288738 0.83 PTGS1 (0.65) PTGS1KMT2AAKR1C3AKR1C2PTGS2
SCHEMBL28133951 0.83 PTGS1 (0.65) PTGS1KMT2AAKR1C3AKR1C2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101475526-B Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof TEXAS BIOTECHNOLOGY CORP 2011-05-25 CN disclosed
US-7812038-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
CN-101475526-A Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof TEXAS BIOTECHNOLOGY CORP (US) 2009-07-08 CN disclosed
CN-100491353-C Carboxylic acid derivatives inhibiting the binding of integrins to their receptors TEXAS BIOTECHNOLOGIES CORP (US) 2009-05-27 CN disclosed
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors BIEDIGER RONALD J 2006-12-07 US disclosed
US-6972296-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. (US) 2005-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, ITGA1 PTGS1 1253/4885KMT2A 3959/4885AKR1C3 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.